Walk into most new biologics facilities being built today — in Singapore, South Korea, Incheon, Penang, or Pasir Gudang — and you’ll find single-use systems at the centre of the manufacturing design.

The biologics manufacturing landscape has changed fundamentally over the past decade. Complex modalities — monoclonal antibodies, gene therapies, cell-based products — demand manufacturing environments where contamination risk is not merely controlled but systematically eliminated.

Asia’s biopharmaceutical industry is no longer just catching up — in several ways, it is setting the pace. From South Korea’s globally competitive CDMOs to the rapid emergence of biotech clusters across Southeast Asia, the region is investing heavily in biologics manufacturing infrastructure.

As the biopharmaceutical industry continues to evolve, single-use systems (SUS) have become a cornerstone of modern manufacturing. Their ability to improve efficiency, reduce turnaround time, and enable flexible facility design has made them the preferred choice across emerging and established markets alike.

Over the past decade, Asia has emerged as one of the fastest-growing hubs for biopharmaceutical manufacturing. Countries across Southeast Asia and South Korea are investing heavily in infrastructure, talent, and innovation to position themselves as global biomanufacturing leaders.